Turtle Cameron 4
4 · Spyre Therapeutics, Inc. · Filed Feb 20, 2024
Insider Transaction Report
Form 4
Turtle Cameron
DirectorChief Executive Officer
Transactions
- Award
Common Stock
2024-02-15$9.82/sh+400$3,928→ 746,907 total
Footnotes (2)
- [F1]These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
- [F2]Includes 493,558 shares of common stock that vest over an approximately three year period, subject to the continuing service of the Reporting Person on each vesting date.